NCT07483294RecruitingPhase 4
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Dec 2029
- Lead sponsor
- Northwell Health
- Diseases
- Schizophrenia
- NCT number
- NCT07483294
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Nov 2025 to the primary completion date, 1 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any medical condition which requires treatment with a medication with psychotropic effects;
Other illness
- Serious neurological or endocrine disorder or brain trauma;
Other
- Significant risk of suicidal or homicidal behavior;
- Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent;
- Contraindications to antipsychotic monotherapy;
- Contraindications to MR imaging (e.g. pacemaker);
- Pregnancy by self report.
Who the study is looking for
- Diagnosis of a first-episode psychotic disorder including: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder Not Otherwise Specified (NOS), bipolar disorder with psychosis, and major depressive disorder with psychosis;
- Current positive symptoms rated \> 3 (moderate) on one or more of the Brief Psychiatric Rating Scale (BPRS) psychosis items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content;
- At early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 8 weeks or less;
- Age 15 to 40;
- Competent to sign informed consent.
Age in the registry: 15 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zucker Hillside Hospital Coordinator of this site? Confirm its status | Glen Oaks | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.